JBIO NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Jade Biosciences, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 19.75 USD
-1.6% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 8.3% above the Trend Line and sits at 61.3% of its 52-week range. The latest completed week returned -1.6%, after a -8.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 33/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 44 out of 100
Latest Close 19.75 USD 31 Jul 2026
1W Return -1.6% latest completed week
4W Return -8.2% short-term follow-through
12W Return -23.5% quarterly tape
Trend Breadth 71.2% 37 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 37-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.6% Latest completed week; four-week move -8.2%. Indicator stack 84/12 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 33/100 conviction; expected move 25.6%. News sentiment 56/100 23 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 8.3% above the Trend Line and sits at 61.3% of its 52-week range. The latest completed week returned -1.6%, after a -8.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5312-week average 0.68

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.53Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.2% over four weeks, -23.5% over 12 weeks, and 186.6% over one year. The current trend has remained active for 37 consecutive weeks.

Performance by holding period

1W-1.6%
4W-8.2%
12W-23.5%
26W26.5%
52W186.6%
Active trend streak37 weeks
Active weeks in one year37
Trend breadth71.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.47Latest activity-pressure read.
Pressure change-367.5%Four-week change in activity pressure.
Leadership23.19Latest relative-leadership reading.
RS change-35.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-10.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-40.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-15.5%
Net share repurchases relative to market value.
Shareholder yield
-15.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

JBIO shows mixed options pressure with a 33/100 conviction score, put-call volume ratio of n/a, expected move of 25.6%, and Sharemaestro trend signal active.

Conviction33/100
Expected move25.6%
Put/call volume
Pressure-5
Speculation0
Volatility96
Trend agreement81
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 23 relevant articles.

6 positive · 16 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move25.6%Nearest-chain priced movement where available.
52-week drawdown-29.5%Distance below the 52-week high.
13-week volatility11.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+30.8%Week of 26 Jun.
Worst week-19.5%Week of 5 Jun.
Latest week-1.6%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains2
Flat weeks0
Modest losses9
Sharp losses8
Recent vol11.5%13-week weekly-return volatility.
Base vol9.5%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew10.7% / -4.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape52/100

Trend, activity pressure, participation, and risk combine to a 52/100 tape read.

 Indicator analysis78/100

Latest 12-week confirmation: trend 12/12, activity pressure 10/12, relative leadership 11/12.

Activity pressure 0.53; No reversal markers Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

JBIO shows mixed options pressure with a 33/100 conviction score, put-call volume ratio of n/a, expected move of 25.6%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 25.6% Sentiment56/100

Weighted news tone is neutral across 23 relevant articles.

Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202619.75 USD-1.6%18.24 USD175.4 USD-0.4723.193.9MOn
24 Jul 202620.08 USD-3.7%18.05 USD178.3 USD-0.3127.653.4MOn
17 Jul 202620.86 USD-0.4%17.93 USD181.3 USD0.0032.115.6MOn
10 Jul 202620.95 USD-2.6%17.80 USD184.3 USD0.1028.595.0MOn
3 Jul 202621.51 USD-2.2%17.60 USD187.4 USD0.1735.704.1MOn
26 Jun 202622.00 USD30.8%17.33 USD190.4 USD0.3741.228.2MOn
19 Jun 202616.82 USD9.6%17.03 USD193.4 USD0.474.418.1MOn
12 Jun 202615.34 USD-9.4%16.87 USD196.2 USD0.72-1.896.3MOn
5 Jun 202616.94 USD-19.5%16.71 USD199.1 USD0.9911.6710.4MOn
29 May 202621.04 USD-5.3%16.45 USD201.9 USD1.2133.702.6MOn
22 May 202622.21 USD-4.9%16.08 USD204.8 USD1.4147.142.6MOn
15 May 202623.36 USD-9.5%15.67 USD207.8 USD1.5459.091.8MOn
8 May 202625.81 USD6.5%15.21 USD211.0 USD1.6378.362.6MOn
1 May 202624.23 USD-3.0%14.65 USD214.7 USD1.5579.803.9MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.